Phase I/II, Randomized, Double-Blind, Placebo-Controlled, Dose-Escalation, Single-Center Study of the Progenitor Cell Mobilizing Effects of Imprime PGG Injection Administered at Varied Dosing Regimens With G-CSF Versus G-CSF Alone in Healthy Subjects

Trial Profile

Phase I/II, Randomized, Double-Blind, Placebo-Controlled, Dose-Escalation, Single-Center Study of the Progenitor Cell Mobilizing Effects of Imprime PGG Injection Administered at Varied Dosing Regimens With G-CSF Versus G-CSF Alone in Healthy Subjects

Completed
Phase of Trial: Phase I/II

Latest Information Update: 27 Sep 2016

At a glance

  • Drugs PGG-glucan (Primary)
  • Indications Chronic lymphocytic leukaemia; Colorectal cancer; Malignant melanoma; Myelosuppression; Non-Hodgkin's lymphoma; Non-small cell lung cancer; Pancreatic cancer; Stem cell mobilisation
  • Focus Adverse reactions
  • Sponsors Biothera
  • Most Recent Events

    • 27 Sep 2016 Results demonstrating the mechanism of action from this study published in the Media Release
    • 27 Sep 2016 According to a Biothera Pharmaceuticals media release, data demonstrating the mechanism of action from this study presented during the CRI-CIMT-EATI-AACR International Cancer Immunotherapy Conference
    • 24 Dec 2014 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top